Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1

Interventions

Peripheral Blood Stem Cell Transplantation 39fludarabine phosphate 37Cyclophosphamide 33Mycophenolic Acid 28Whole-Body Irradiation 24Cyclosporine 24Tacrolimus 22Radiotherapy 19Methotrexate 18Busulfan 18Antilymphocyte Serum 17Flow Cytometry 14Filgrastim 14Etoposide 14Vorinostat 11Bortezomib 11Bexarotene 11mogamulizumab 10Methylprednisolone 10Lenalidomide 10pembrolizumab 9Rituximab 9Melphalan 9Gemcitabine 9Brentuximab Vedotin 9romidepsin 8Therapeutics 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Methoxsalen 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × magrolimab × Lymphoid × Clear all
NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡